RecruitingPhase 4

Vaccine Effectiveness of a Bivalent RSV Prefusion F Protein-Based Vaccine for Preventing RSV Hospitalizations in Adults

Denmark, Spain690,000 participantsStarted 2024-11-18

Plain-language summary

The purpose of this pragmatic randomized trial is to evaluate the vaccine effectiveness of bivalent RSV prefusion F vaccine (RSV vaccine) in adults. Participants will be randomized 1:1 to either RSV vaccine or no RSV vaccine.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria * Age 18 years and above * Informed consent form has been signed and dated Exclusion Criteria: * There are no specific exclusion criteria for this study

What they're measuring

Hospitalization for RSV-related respiratory tract disease

Timeframe: ≥14 days after initially booked vaccination/ information visit date up to 8 months

Trial details

NCT IDNCT06684743

SponsorTor Biering-Sørensen

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2028-05

Contact for this trial

Mats H Lassen, MD

+4529806779 mats.christian.hoejbjerg.lassen@regionh.dk

View on ClinicalTrials.gov More RSV trials